TET2 anticorps (Internal Region)

N° du produit ABIN569654

Détail du produit anti-TET2 anticorps

Antigène: TET2 (Tet Methylcytosine Dioxygenase 2 (TET2))

Épitope: Internal Region

Reactivité: Humain, Souris, Chien

Hôte: Chèvre

Clonalité: Polyclonal

Conjugué: Cet anticorp TET2 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Séquence: C-PHPQSNNDQQ REGSF

Specificité: This antibody is expected to recognize both reported isoforms (NP_001120680.1 and NP_060098.3).

Réactivité croisée (Details): Species reactivity (expected):Mouse and Canine (Dog).
Species reactivity (tested):Human.

Purification: Ammonium Sulphate Precipitation followed by antigen Affinity Chromatography using the immunizing peptide

Immunogène: Peptide with sequence from the internal region of the protein sequence according to NP_001120680.1 and NP_060098.3. Genename: TET2

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Tris saline, pH ~7.3 with 0.02 % Sodium Azide and 0.5 % BSA

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur TET2

Antigène: TET2 (Tet Methylcytosine Dioxygenase 2 (TET2))

Autre désignation: TET2 (TET2 Produits)

Synonymes: anticorps KIAA1546, anticorps MDS, anticorps Ayu17-449, anticorps E130014J05Rik, anticorps mKIAA1546, anticorps RGD1311625, anticorps tet methylcytosine dioxygenase 2, anticorps TET2, anticorps Tet2

Sujet: TET2 is frequently mutated in myelodysplastic syndromes, a heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. It Catalyzes the conversion of methylcytosine (5mC) to 5-hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation. TET2 is Broadly expressed. Highly expressed in hematopoietic cells, highest expression observed in granulocytes. Expression is reduced in granulocytes from peripheral blood of patients affected by myelodysplastic syndromes.Synonyms: KIAA1546, Methylcytosine dioxygenase TET2

ID gène: 54790

NCBI Accession: NP_001120680

UniProt: Q6N021

Pathways: L'effet Warburg